Predicting In Vivo Payloads Delivery using a Blood-brain Tumor-barrier in a Dish
April 16th, 2019
11.4K views
Drug targeting to central nervous system tumors is a major challenge. Here we describe a protocol to produce an in vitro mimic of the blood-brain tumor-barrier using murine and/or human cells and discuss their relevance for the predictability of central nervous system tumor targeting in vivo.
Overview
This article presents a protocol for creating an in vitro model of the blood-brain tumor barrier using murine and human cells. The model aims to enhance the predictability of drug targeting to central nervous system tumors.
Key Study Components
Area of Science
- Neuroscience
- Pharmacology
- Cell Biology
Background
- Drug delivery to brain tumors is complicated by the blood-brain barrier.
- Current methods often rely on animal models, which can be limiting.
- In vitro models can provide a more controlled environment for testing.
- Utilizing immortalized and patient-derived cells can enhance the model's relevance.
Purpose of Study
- To develop a reproducible in vitro model of the blood-brain tumor barrier.
- To assess drug diffusion and targeting capabilities of therapeutic compounds.
- To reduce reliance on animal models in early drug testing.
Methods Used
- Creation of a blood-brain tumor barrier model using cell culture techniques.
- Use of immortalized murine and human cells for flexibility.
- Quantification and visualization of drug passage through the barrier.
- Immunofluorescence imaging for assessing cell interactions.
Main Results
- The model allows for high reproducibility in drug testing.
- Patient-derived cells help to account for tumor heterogeneity.
- Visual protocols enhance understanding of cell seeding techniques.
- Successful demonstration of drug delivery mechanisms in vitro.
Conclusions
- This in vitro model is a valuable tool for drug development targeting brain tumors.
- It provides insights into the efficacy of therapeutic compounds before in vivo testing.
- Future studies can expand on this model to include more complex tumor environments.
Frequently Asked Questions
What is the blood-brain barrier?
The blood-brain barrier is a selective permeability barrier that protects the brain from harmful substances while allowing essential nutrients to pass through.
Why is drug delivery to brain tumors challenging?
The blood-brain barrier restricts the entry of many therapeutic agents, making it difficult to deliver effective concentrations of drugs to brain tumors.
How does this model improve drug testing?
This model allows for controlled in vitro testing of drug diffusion and targeting, reducing the need for animal models and improving predictability.
What types of cells are used in this model?
The model utilizes both immortalized murine and human cells, as well as patient-derived brain tumor cells.
What techniques are used to visualize drug passage?
Immunofluorescence imaging is employed to visualize and quantify the interaction between drugs and the cells in the model.
Can this model be scaled up for high-throughput screening?
Yes, the method is designed to be scalable, allowing for the screening of multiple compounds simultaneously.
What are the implications of this research?
The findings could lead to more effective treatments for brain tumors by improving the understanding of drug delivery mechanisms.
Executive Industry Relevance
Accurate prediction of in vivo payload delivery across the blood-brain tumor barrier remains a critical bottleneck in CNS drug development, where poor translatability of in vitro models leads to late-stage attrition. This in vitro BBTB model enables mechanistic de-risking by quantifying nanoparticle transcytosis and tumor targeting in a reproducible, human-relevant system. By reducing reliance on animal models and supporting high-throughput screening, it improves predictive confidence in lead identification and portfolio triage for brain-targeted therapeutics.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses regarding barrier permeability and tumor-specific delivery mechanisms.
- Operational Value: Supports functional target validation by correlating nanoparticle passage with cellular localization in endothelial, astrocytic, and tumor compartments.
Screening & Assay Development
- Scientific Value: Provides quantitative fluorescence readouts to compare transcytosis efficiency of nanoparticles across size and surface modifications.
- Operational Value: Uses immortalized cell lines for scalable, reproducible assays compatible with 96-well plate formats and plate reader quantification.
Translational & Preclinical Research
- Scientific Value: Demonstrates correlation between in vitro nanoparticle passage and in vivo behavior, enabling preclinical predictability.
- Operational Value: Incorporates patient-derived glioblastoma spheres to capture tumor heterogeneity and improve translational relevance.
Pipeline & Workflow Integration
The BBTB model fits within the discovery continuum from early target validation through lead identification, offering a predictive bridge to preclinical studies by measuring functional drug delivery prior to in vivo testing.
- Discovery Biology: Supports hypothesis testing of barrier properties and mechanistic de-risking of delivery vehicles through quantitative transcytosis assays.
- Screening: Enables assay readiness with standardized cell seeding, real-time permeability measurements, and confocal imaging for compound evaluation.
- Analytics: Generates quantitative fluorescence data from blood and brain compartment samples to assess nanoparticle passage kinetics and selectivity.
- Translational Research: Connects in vitro findings to preclinical continuity by showing predictive alignment with in vivo nanoparticle distribution in murine models.
- Enterprise Reuse: Establishes a reusable platform for screening diverse antitumor agents and adapting to other CNS barriers or neurodegenerative disease models.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in BBB penetration, reduction of mechanistic ambiguity in drug delivery, and target validation via spatial tracking of nanoparticles.
- Operational Value: Standardization through defined cell densities, insert-based culture, and reproducible barrier formation validated by tight junction protein localization.
- Strategic Value: Better go/no-go decisions on lead compounds, capital efficiency via reduced animal use, and de-risking of CNS delivery mechanisms.
- Portfolio Impact: Risk-adjusted prioritization of nanoparticles based on demonstrated transcytosis and tumor co-localization, enabling data-driven advancement decisions.
Implementation Considerations
- Requires expertise in cell culture techniques, including sterile handling of inserts, cell dissociation, and layer-specific seeding under a biosafety hood.
- Dependent on instrumentation such as centrifuges, plate readers for fluorescence quantification, and confocal microscopes for imaging tight junctions and nanoparticle localization.
- Necessitates cross-team standardization of cell preparation protocols, medium formulations, and timing of medium exchanges to ensure barrier integrity.
- Involves adaptation considerations when scaling to different insert pore sizes or substituting cell types to model other cellular barriers.
- Includes practical limitations such as membrane fragility during handling, potential for leakage if damaged, and the need for careful membrane extraction using sterile tools to avoid artifacts.
Biopharma FAQs
Why does quantifying nanoparticle transcytosis matter for target validation?
Quantifying nanoparticle transcytosis across the in vitro BBTB mimic provides measurable evidence of delivery capability, enabling teams to validate whether a therapeutic payload can reach the tumor site. This supports target validation by linking nanoparticle properties to functional brain penetration, reducing reliance on cytotoxicity alone as a proxy for efficacy.
How does isolating independent variables like nanoparticle size improve discovery pipeline decisions?
By testing nanoparticles of defined sizes (e.g., NP110 vs NP350) under identical conditions, the model isolates size as an independent variable to assess its impact on barrier passage. This enables clear structure-property relationships that inform lead selection and help prioritize compounds with favorable delivery profiles early in the pipeline.
What do quantitative dependent variable measurements enable in assay interpretation?
Measuring fluorescence intensity in blood and brain compartments over time provides a quantitative dependent variable that reflects nanoparticle permeation kinetics. These measurements allow comparison of delivery efficiency, calculation of permeability values, and identification of compounds that successfully traverse the barrier versus those retained in the blood compartment.
Why are replication requirements important for cross-functional collaboration?
Replication across multiple inserts and experimental runs ensures data reproducibility, which is essential for building confidence in results shared between discovery, preclinical, and translational teams. Consistent barrier formation, validated by zonula occludens-1 and claudin-5 localization, supports reliable data transfer and reduces variability in cross-functional decision-making.
What statistical analysis capabilities are required before implementing this assay?
Implementation requires the ability to collect time-point samples, quantify fluorescence via plate reader, and perform comparative statistical analysis (e.g., t-tests or ANOVA) to determine significant differences in nanoparticle passage between experimental groups. This enables objective assessment of delivery performance and supports data-driven go/no-go criteria for lead compounds.
Chapters in this video
0:04
Title
2:12
Preparation of Astrocytes
4:08
Preparation of Endothelial Cells
6:10
Preparation of Glioma Cells
7:43
Measurement of the BBTB Mimic Permeability (Optional)
8:48
BBTB Fluorescence Staining to Detect Nanoparticle Transcytosis
10:08
Results: Analysis of In Vivo Payload Delivery using the Blood-brain Tumor-barrier
12:25
Conclusion
